AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s ...

AbbVie (NYSE:ABBV) said it expects to record an impairment charge of approximately $3.5B related to the drug emraclidine, ...

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its ...

The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma ...

In a regulatory filing, AbbVie (ABBV) stated, “On January 9, 2025, AbbVie determined that it will record an impairment charge related to the ...

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

Michele Buck, a 20-year veteran of Hershey who assumed leadership in 2017, said she would step down from her roles as president and chief executive on June 30, 2026. The merger combines two of the ...

Drugmaker AbbVie warned it will post a $3.5 billion impairment charge related to last year's $8.7 billion bet on Cerevel Therapeutics following the failure of the deal's key drug candidate, a ...

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma moved to simplify its corporate structure and Biogen made another hire.

Calling people "mentally ill" based on their sexual identity and referring to women as "household objects" will now be allowed in the context of political discussions on social media giant Meta's ...

Companies seeking to benefit from campaign promises to cut regulations and taxes are ditching diversity and climate initiatives; ‘EVERYBODY WANTS TO BE MY FRIEND!!!’ ...